Welcome to our dedicated page for Allovir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on Allovir stock.
The AlloVir, Inc. (ALVR) news page on Stock Titan aggregates company communications and third-party coverage related to its activities as an allogeneic T cell immunotherapy developer and its planned merger with Kalaris Therapeutics, Inc. AlloVir describes itself as a late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised pediatric and adult patients. Its disclosures highlight an off-the-shelf, allogeneic virus-specific T cell platform and a pipeline led by the multi-virus-specific T cell therapy posoleucel.
Readers following ALVR news can find updates on clinical trial progress and outcomes, including Phase 2 and Phase 3 studies of posoleucel in allogeneic hematopoietic cell transplant recipients and adult kidney transplant recipients with BK viremia. Company releases have discussed prevention and treatment trials targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, and JC virus, as well as early-stage work on ALVR106 for respiratory viruses and ALVR107 for chronic hepatitis B infection.
News items also cover strategic and corporate developments. AlloVir has reported discontinuation of its three Phase 3 posoleucel studies after pre-planned futility analyses, along with a shift toward capital preservation and review of strategic alternatives. Subsequent announcements describe a definitive all-stock merger agreement with Kalaris Therapeutics, stockholder approval of that merger, and expectations that the combined company will operate as Kalaris Therapeutics, Inc. and trade on Nasdaq under the ticker KLRS, subject to customary closing conditions.
In addition, the ALVR news feed may include information on financings, investor conference participation, and regulatory designations such as RMAT, Orphan Drug, and PRIME status for posoleucel. Investors and researchers can use this page to monitor how AlloVir’s virus-specific T cell programs and its transition toward a retina-focused combined company with Kalaris are described over time.
AlloVir (Nasdaq: ALVR) appointed Shawn Tomasello to its Board of Directors, bringing over 35 years of experience in the life sciences sector, particularly in cell and gene therapy. Tomasello has a significant track record, including her role as Chief Commercial Officer at Kite Pharma. This strategic addition aims to drive AlloVir’s evolution into a commercial-stage company, enhancing its multi-virus specific T cell platform. Longstanding Board member John Wilson will retire following the 2022 annual meeting, marking a transition in the company’s leadership.
AlloVir has initiated a Phase 3 study of posoleucel, an allogeneic T-cell therapy for preventing viral infections in high-risk hematopoietic cell transplant patients. Preliminary Phase 2 data presented at the EBMT Annual Meeting show that 21 of 24 patients remained free of significant infections through Week 14. Posoleucel targets six life-threatening viruses, with a potential market of 40,000 patients annually. The study will enroll approximately 300 patients, assessing safety and efficacy through a 14-week interval.
AlloVir (NASDAQ: ALVR) announced that CEO Diana Brainard will engage in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:00 a.m. EST. The live webcast will be accessible on AlloVir's Investors & Press section, with a replay available for 30 days post-event.
AlloVir focuses on allogeneic T cell immunotherapy, aiming to restore immunity against viral diseases in patients with weakened immune systems. The company is advancing several mid- and late-stage clinical trials and utilizes innovative technology for treating multiple viral infections.
AlloVir (ALVR) reported its 2021 financial results, revealing a net loss of
AlloVir has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its lead product, posoleucel, aimed at treating adenovirus (AdV) infections post-allogeneic hematopoietic stem cell transplant. This follows positive results from the Phase 2 CHARMS study. The company has also initiated a Phase 3 registrational study for posoleucel and is enrolling patients. Additionally, a Phase 1/2 trial for ALVR106, targeting respiratory viral infections, is also underway.
AlloVir (NASDAQ: ALVR), a clinical-stage allogeneic T-cell immunotherapy company, announced that CEO Diana Brainard will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. An audio-only webcast will be available on the AlloVir website, with an archived replay accessible for 30 days post-presentation. AlloVir develops innovative therapies to combat life-threatening viral diseases in patients with weakened immune systems, utilizing single- and multi-virus-specific T cells in its clinical trials.
AlloVir (Nasdaq: ALVR) announced the departure of Chief Medical Officer Dr. Augustin Melian at year-end 2023. Dr. Melian joined the company in March 2019 and significantly advanced the clinical development of its lead product, posoleucel. He will assist in transitioning to ensure continuity. Richard Riese, SVP of Clinical Research, will oversee ongoing clinical programs, including the Phase 3 studies for posoleucel. AlloVir focuses on innovative cell therapies targeting life-threatening viral diseases for patients with weakened immune systems.
AlloVir has announced preliminary data from a Phase 2 study of posoleucel for preventing viral infections in high-risk allogeneic hematopoietic cell transplant patients. Out of 23 patients, only three clinically significant infections occurred, and no end-organ viral disease was reported. With 11 of 13 patients free from significant infections through Week 14, the data supports advancing posoleucel into a Phase 3 trial, expected to begin in 1H 2022. The findings highlight the potential for posoleucel to transform treatment for vulnerable patient populations.
AlloVir (NASDAQ: ALVR) will host a virtual investor event on December 13, 2021, at 8:00 a.m. EST, providing a corporate update and initial data from its Phase 2 study of posoleucel for multi-virus prevention. This investigational therapy targets six life-threatening viruses in allo-HSCT recipients. Key speakers include CEO Diana Brainard and Dr. Sanjeet Dadwal, who will discuss the risks of viral infections. A live webcast will be available on the AlloVir website, with an archived replay for 30 days.
AlloVir, Inc. (Nasdaq: ALVR), a clinical-stage cell therapy company, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded fireside chat will be available from November 22 to December 2, 2021, accessible on the conference website and AlloVir's Investor section at ir.allovir.com. AlloVir focuses on restoring immunity against viral diseases, utilizing innovative allogeneic T cell therapies to treat patients with weakened immune systems. For more details, visit www.allovir.com.
FAQ
What is the current stock price of Allovir (ALVR)?
What is the market cap of Allovir (ALVR)?
